Highlights Newsletter 3 This newsletter presents you the following key sessions: Watch the video interview with Prof. dr. H. Wildiers about the landmark phase III MONALEESA-2 trial: ribociclib improved progression-free survival with limited toxicity in HR-positive, advanced breast cancer First-line pembrolizumab plus chemotherapy prolongs survival in advanced non-small cell lung cancer with a high PD-L1 expression Adjuvant sunitinib prolongs the disease free survival of patients with locoregional clear-cell renal cell carcinoma Ceritinib is superior to chemotherapy in pretreated patients with ALK-rearranged non-small-cell lung cancer Nivolumab maintains function and reduces symptom burden in patients with recurrent metastatic head and neck cancer